Indication
Non-small Cell Lung
4 clinical trials
8 products
2 drugs
Clinical trial
Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationStatus: Terminated, Estimated PCD: 2014-07-23
Product
DasatinibProduct
ASN003Clinical trial
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2019-02-01
Clinical trial
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2027-04-14
Product
JNJ-86974680Product
CetrelimabClinical trial
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Product
AmivantamabDrug
LazertinibDrug
AN0025Product
PemetrexedProduct
Direct Oral AnticoagulantProduct
Low Molecular Weight Heparin